Skip to main content

Joltid

Press Releases

METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager

HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ — METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology…

Read the full release →

News provided by PR Newswire.